Ascentage Pharma Group International cash flow statement

In fiscal 2025, Ascentage Pharma Group International's operations generated −$163m of cash; it spent $3.8m on capital projects, leaving free cash flow of −$167m. It returned $1.3m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ascentage Pharma Group International: cash flow statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−97	−103	−15	−163
Depreciation and amortisation	2	2	2	1
Stock-based pay	3	4	3	3
Capital spending	30	7	3	4
Free cash flow	−128	−109	−19	−167
Free cash flow after stock pay	−131	−114	−22	−170
Share buybacks	4	1	—	1

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AAPG vs ADCT AAPG vs PLX AAPG vs BCYC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ascentage Pharma Group International's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ascentage Pharma Group International.